Estrogen loss may cause Alzheimer’s in women—should that change HRT counseling?

For clinicians counseling patients about hormone replacement therapy (HRT), the hardest conversations often begin with a simple question: “Will this protect my brain?”

Though it's not time to say that HRT prevents Alzheimer's, the biology is menopause and brain aging is becoming harder to ignore.

The current clinical conversation around HRT is moving toward more nuance: timing, formulation, and indication matter, and dementia prevention remains an unproven indication.

Estrogen loss and the brain’s overlooked scaffolding

The researchers used genetically modified mouse models lacking aromatase, the key enzyme for estrogen biosynthesis.^[]

By comparing young and old male and female mice with whole-body or brain-specific estrogen deficiency, investigators tried to isolate the effect of local brain estrogen loss.

The study suggests that after menopause, estrogen loss may affect the brain’s support architecture, not only neurons or amyloid plaques.

“We have provided some of the most compelling evidence that estrogen is so important for memory function and other mood functions in the female brain,” said study author Serdar Bulun, MD, in a press release. “This should motivate clinicians to be more aware of the essential role of estrogen for women’s brains, because once memory is gone, it’s gone.”^[]

That framing is useful because many patients now hear about Alzheimer’s through the lens of amyloid clearance, anti-amyloid monoclonal antibodies, and biomarker testing. 

This study points to another possible pathway: The tissue environment around neurons may help explain why women carry a disproportionate Alzheimer’s burden.

Why this lands in a charged HRT moment

HRT has been undergoing a reputational reset. Many clinicians were trained in the long shadow of the Women’s Health Initiative (WHI), when hormone therapy quickly became synonymous with breast cancer and cardiovascular risk.^[]

More recently, menopause specialists have pushed back against overly broad avoidance, arguing that the original WHI population and regimens are often overgeneralized to younger, symptomatic women near the menopause transition. 

The Menopause Society’s 2022 position statement emphasizes that hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, and that it can prevent bone loss and fracture.^[]

For healthy women younger than 60 years or within 10 years of menopause onset, the benefit-to-risk ratio is generally favorable when treating bothersome vasomotor symptoms or preventing bone loss.^[]

That is different from prescribing HRT to prevent dementia. Hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia. Conjugated equine estrogens plus medroxyprogesterone acetate in the WHI Memory Study-era data has been associated with increased dementia risk in women aged 65 years and older. ^[]

What doctors can say in the exam room

A practical counseling script might sound like this:

That response does a few useful things: It validates the patient’s concern, acknowledges the science, avoids overstating the evidence, and brings the conversation back to individualized prescribing.

The decision point is whether a symptomatic patient near menopause, without contraindications, might benefit from systemic therapy at the lowest effective dose with periodic reassessment. 

For isolated genitourinary syndrome of menopause, local vaginal estrogen or other local therapies may be more appropriate than systemic HRT.

Where this study may change the conversation

Alzheimer’s risk in women is often discussed in broad epidemiologic terms: Women live longer, women develop more Alzheimer’s disease, and menopause may play a role. 

Future studies may need to stratify by age at initiation, years since menopause, ovarian status, APOE genotype, baseline cognition, amyloid and tau status, sleep, vascular risk, estradiol formulation, progestogen type, and route of administration.

Your takeaway

This study should not prompt clinicians to prescribe HRT for Alzheimer’s prevention. It should prompt more informed counseling.

For a 68-year-old who is asymptomatic and wants to start systemic HRT solely to protect memory, the answer remains no.